

Remarks


Claims 1-15, 19-23 and 28 have been cancelled without waiver or prejudice and without admitting anticipation or obviousness. Applicants reserve the right to claim any non-elected subject matter included in the cancelled claims in subsequent divisional applications. Support for the addition of New Claims 30 through 44 may be found generally throughout the specification; specifically, on pages 14-30; and more specifically, in the following corresponding locations in the specification.

Claims 30 and 31: pg 18, line 9 - pg 19, line 2
Claim 32: pg 18, lines 4 – 16
Claim 33: pg 16, lines 6-7
Claim 34: pg 19, lines 14-25
Claim 35: pg 16, line 8; and pg 20, line 5
Claims 36 – 43: pg 29, lines 1-6
Claim 44: pg 26, line 18 - pg 28, line 34

Amendments to Claims 16-18, 24-27 and 29 were made to correct improper references, redundancies, improper antecedent basis, and general grammatical errors. No substantive new matter was added to these claims.

Respectfully Submitted By:

October 15, 2003



Arlene K. Musser
Registration No. 37,895

Pfizer Inc.
Patent Department, MS: 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871